Autopsy report · NCT04956302

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

“PI Decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Abdullah Khan

Sponsor type

University, hospital or other

Conditions

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma

Interventions

Bortezomib; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Panobinostat Lactate

Participants

1

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.